National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-CD19 fully human monoclonal antibody MDX-1342
A fully human anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential antineoplastic activity. Anti-CD19 monoclonal antibody MDX-1342 binds to CD19, depleting and eliminating CD19-expressing B-cells. CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:MDX-1342



Previous:Antabuse, anti-1-amino-3-[18F ]fluorocyclobutane-1-carboxylic acid, anti-B4 blocked ricin immunotoxin, anti-CCL-2 human monoclonal antibody CNTO 888, anti-CD137 monoclonal antibody
Next:anti-CD19-DM4 immunoconjugate SAR3419, anti-CD20 monoclonal antibody AME-133v, anti-CD20 monoclonal antibody R7159, anti-CD200 monoclonal antibody ALXN6000, anti-CD22 immunotoxin CAT-8015

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov